Analysis of the Long-Term Prognosis in Japanese Patients with Ulcerative Colitis Treated with New Therapeutic Agents and the Correlation between Prognosis and Disease Susceptibility Loci

• Published in: Inflammatory intestinal diseases 2021-09, Vol.6 (3), p.154-164
• Main Authors: Hishinuma, Kasumi, Moroi, Rintaro, Okamoto, Daisuke, Shimoyama, Yusuke, Kuroha, Masatake, Shiga, Hisashi, Kakuta, Yoichi, Kinouchi, Yoshitaka, Masamune, Atsushi
• Format: Article
• Language: English
• Subjects: biologic agents; biomarkers; genetic susceptibility; inflammatory bowel disease; Research Article; ulcerative colitis
• ISSN: 2296-9403; 2296-9365
• DOI: 10.1159/000518371

Background: New therapeutic agents, including biologics and small-molecule drugs, are widely used to treat ulcerative colitis (UC). This study evaluates long-term prognosis in Japanese patients treated with these agents and the association between prognosis and genetic susceptibility to UC. Methods: We evaluated surgery-free rates using the Kaplan-Meier method in the total cohort and in patients treated with prednisolone and new therapeutic agents. Multivariate analysis was performed to identify clinical factors affecting surgical rates using Cox’s proportional hazard model. The rate of use of new therapeutic agents was compared using the Kaplan-Meier method, and multivariate analysis was conducted to investigate the correlation between the single-nucleotide polymorphism (SNP) rs117506082 and long-term prognosis. Results: Surgery-free survival decreased over time. There was no significant difference in this parameter between patients who were administered prednisolone and those who were administered new therapeutic agents. Poor response to prednisolone and treatment without topical 5-aminosalicylic acid were poor prognostic factors. Shorter time from diagnosis to initiation of treatment with new therapeutic agents was a risk factor for colectomy. The AA genotype of SNP rs117506082 was associated with a shorter time to surgery and increased use of new therapeutic agents. Conclusions: The use of new therapeutic agents might improve long-term prognosis in patients with more severe UC. Previously identified genetic risk factors were not significantly associated with a higher rate of colectomy.